We consider inference for longitudinal data based on mixed-effects models with a non-parametric Bayesian prior on the treatment effect. The proposed non-parametric Bayesian prior is a random partition model with a regression on patient-specific covariates. The main feature and motivation for the proposed model is the use of covariates with a mix of different data formats and possibly high-order interactions in the regression. The regression is not explicitly parameterized. It is implied by the random clustering of subjects. The motivating application is a study of the effect of an anticancer drug on a patient's blood pressure. The study involves blood pressure measurements taken periodically over several 24-h periods for 54 patients. The 24-h periods for each patient include a pretreatment period and several occasions after the start of therapy.
INTRODUCTION
We consider semiparametric Bayesian inference for repeated measurement data. We propose a mixedeffects model based on a random partition of experimental units into clusters. The random partition model includes a regression on covariates specific to each experimental unit. The main advantage of the proposed model is the flexible nature of this indirect regression that naturally allows the inclusion of different data formats and easily adapts to allow inference on high-order interactions. Rather than being specified up front in a parametric model, interactions are discovered as summaries of posterior clustering.
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Mixed-effects models provide a natural setting for non-parametric Bayesian approaches. In particular, modeling random-effects distributions is a traditional application for non-parametric Bayesian models of random probability measures. Typical examples are Dirichlet process (DP) and DP mixture models for pharmacokinetic (PK) parameters in population PK models (Müller and Rosner, 1997) or nonparametric priors for subject-specific effects in repeated measurement models (Kleinman and Ibrahim, 1998; Zhang and others, 2010; Yang and others, 2010) . For a recent review of semiparametric randomeffects models in biomedical inference, see, for example, Ohlssen and others (2007) . One of the reasons for the popularity of the DP prior, especially in the context of biomedical studies, is the implied clustering of experimental units. We introduce some notation to describe this partition. In the following discussion, we will assume that the experimental units are patients and the random effects are patient-specific. Let z i denote patient-specific effects for patients i = 1, . . . , n, and let G(z i ) denote the random-effects distribution and assume a non-parametric DP prior on G, as is the case in many Bayesian semiparametric models. One of the implications of a DP prior on G is the almost surely discreteness of G, leading to ties among the z i . The configuration of ties can be characterized as a partition of patients into clusters. Thus, a DP prior on a random-effects model implicitly defines a prior on clustering patients. Let ρ = {S 1 , . . . , S J } denote a partition of the patient indices S = {1, . . . , n} into non-overlapping clusters S j ⊂ S with S = j S j . Let z j , j = 1, . . . , J denote the J n unique values among z i ∼ G, i = 1, . . . , n. The DP prior implicitly defines a prior p(ρ) for clusters defined as S j = {i : z i = z j }.
Several recent approaches have developed the theme of priors p(ρ). In particular, in most studies some patient-specific baseline covariates, x i , i = 1, . . . , n, are available that can be exploited to improve the clustering. Typical examples are age, prior treatment history, biomarkers, etc. MacEachern (1999) extended the DP prior for a random distribution G to a prior model for a family of distributions {G x , x ∈ X }. The model is known as the dependent DP (DDP). Assume z i | x i = x ∼ G x , for patients i = 1, . . . , n, with a DDP prior on {G x , x ∈ X }. In one variation of the DDP prior, the model includes positive prior probability for ties {z i 1 = z i 2 } for any two patients i 1 , i 2 . Again, the model implicitly defines a prior for clustering patients, p(ρ | x), now indexed by the covariates x = (x 1 , . . . , x n ). The DDP model has become the most popular prior model for families of random probability models. See, for example, Barrientos and others (2012) for a review of the recent literature.
The use of non-parametric Bayes priors in mixed-effects models need not be restricted to randomeffects distributions. Especially when the random probability measure G x is indexed by covariates, like in the DDP, it becomes meaningful to use G x (·) as a hierarchical prior for treatment effects. For example, De Iorio and others (2009) use a DP mixture prior for treatment effects in a survival regression. An important limitation of the DDP model and its variants, however, is that the nature of the dependence on the covariates is fixed. In particular, the posterior predictive distribution only includes interactions of covariates if those interactions are explicitly characterized in the model. Some DDP variations add some flexibility by adding variable selection to mitigate this restriction. In Müller and others (2011) , we define an alternative model for p(ρ | x). In this paper, we build on this model for p(ρ | x) to develop an approach for covariate-dependent clustering in mixed-effects models. We discuss computational strategies to implement inference in the context of a typical repeated measurement model.
A CLINICAL STUDY OF SORAFENIB
Study design and data
The motivating case study concerns the effect of a new class of anticancer drugs on the blood pressures of patients. These drugs are designed to interfere with the function of endothelial cells, the cells that line the inner surfaces of blood vessels. These cells lead the formation of new branches from existing blood vessels. This process, angiogenesis, is necessary to support the growth and spread of tumors. By targeting the vascular endothelial growth factor (VEGF) signaling pathway, which is important to the growth, migration, and survival under stress of endothelial cells, these drugs have been proved to extend survival in patients with a variety of common cancers. The particular drug that the investigators studied, sorafenib, is taken orally and received regulatory approval in the United States for treatment of cancers of the kidney and liver.
Targeting VEGF signaling is not without complications. In particular, the VEGF signaling pathway has been shown to be one way by which endothelial cells regulate blood pressure. Some patients have developed life-threatening complications from VEGF signaling pathway inhibitors due to severely elevated blood pressure. On the other hand, some studies have shown modest increases in blood pressure to be associated with better treatment outcomes with these drugs.
One of us (Michael L. Maitland) and colleagues wished to measure blood pressure responses to sorafenib with maximal precision. The study design called for patients to wear a device that automatically measured the patient's systolic (SBP) and diastolic (DBP) blood pressure periodically during a 24-h period. Patients wore the device prior to starting treatment with sorafenib and on several occasions after starting treatment with the drug. During each 24-h period, the machine measured blood pressures every 15 min during the daytime and every 30 min at night. Recognition that a person's blood pressure oscillates over the course of a day has led to the use of the midline as a summary to characterize a person's blood pressure. This central value is called the MESOR (for midline estimating statistic of rhythm) and is the mean value around which the blood pressures vary throughout the day. If a patient experiences hypertension, then the MESOR will increase. The MESOR, therefore, provides a convenient measure for examining associations between patient characteristics and blood pressure change in response to the drug. We sought to determine relationships between patient covariates and the effect of sorafenib on blood pressure with as few modeling assumptions as possible.
Fifty-four patients took part in the study. They wore the SunTech Oscar device (Morrisville, NC, USA) that collected blood pressure measurements over 24 h on multiple occasions. The device measured both SBP and DBP. The study collected baseline blood pressure measurements within 10 days prior to the start of sorafenib. All patients in the study received sorafenib orally twice a day at a dose of 400 mg, starting on occasion 2. In addition to the pretreatment and initial on-study, each patient contributed measurements on one or two more occasions. In all, 27 patients had day 1 sessions; all typically had the next session between days 6 and 10, and the next between days 35 and 42. There were an average ofn ic = 62 SBP and DBP measurement pairs per session. The data set included several baseline covariates for each patient, x i , = 1, . . . , 8, including age (AGE); height (HGT); weight (WGT); body mass index (BMI); albumin (ALB); sex (SEX), with SEX = 1 if male; BPM, an indicator of whether the patient was taking a bloodpressure (anti-hypertension) medication at baseline; and race (RACE), coded as RACE = 1 if white nonhispanic and RACE = 0 otherwise. The first five covariates are continuous. BMI is a derived covariate, computed as WGT (kg)/{HGT(m)
2 }. Figure 1 shows the blood pressure data on each occasion for the first three patients.
Regression through random partitions
We use a second-order harmonic model to characterize blood pressure over time. Let y ick = (y ick0 , y ick1 ) denote diastolic (0) and systolic (1) pressure for patient i, occasion c, repeated measurement k. Let t ick denote the time (in hours) within occasion c at time k. We implement inference for diastolic and SBP separately and henceforth only use a scalar y ick . We use notation
Let T = 24 denote the daily periodicity. We use a 5D random-effects vector
) and an effect on the MESOR, δ i , for sorafenib. The treatment effect is indexed by i in anticipation of later adding a regression on
. We assume at time t ick
Here, W ict is the design vector given by the harmonic functions. The first term adds the effect of sorafenib treatment for observations after the pretreatment session c = 1, the baseline occasion preceding the start of sorafenib treatment. The model assumes a constant effect δ i across all sessions c 2 after treatment. Patients in the study took the drug twice daily, and occasions were weeks apart. So patients were at steady state and there was no expectation for further change in blood pressure (Maitland and others, 2009 ). This assumption is also confirmed by inspection of the data in Figure 1 . The main inference question concerns the effect of sorafenib on a new patient's MESOR blood pressure (δ n+1 ), given the patient's baseline covariates x n+1 and information about the patient's blood pressure y n+1,1 without sorafenib. Inference about δ n+1 as a regression on x n+1 would make it possible to identify subpopulations of patients who are likely to become hypertensive by the treatment and facilitate treatment individualization as a function of patient-specific covariates. The main challenge is the problem that subgroups of interest are most likely to be characterized by interactions of covariates, including possibly non-linear functions of the continuous covariates.
We propose an approach using regression based on random partitions. In words, the proposed inference approach is based on implementing the regression indirectly, by random clustering of patients, and assuming a common treatment effect for all patients in a cluster. We argue that random partitions of the patient population can replace a flexible regression model for a treatment effect. The basic approach can be described without technical details. Let s i , i = 1, . . . , n, n + 1, denote cluster membership indicators that index a random partition ρ = {S 1 , . . . , S J } of the patients, with s i = j if i ∈ S j . Let δ j denote a cluster-specific treatment effect. Let x j = (x i ; i ∈ S j ) denote the covariates arranged by cluster, let
conditional on (ρ, δ ) and already marginalized with respect to the remaining random effects. Here G 0 is the prior on the cluster-specific treatment effects δ j . The final prediction is then also appropriately averaged with respect to the posterior distribution p(ρ, δ | data). An important feature of (2.2) is that arbitrarily complicated interactions of covariates are encoded in the clustering ρ. Any interactions that are present in the actual data (x i , i = 1, . . . , n) can be represented.
MODEL
We build on (2.1) to define a mixed-effects model. The model definition proceeds in two steps. First we define a random partition ρ of the patients S = {1, . . . , n} into subgroups S j ⊂ S, j = 1, . . . , J . The random partition includes a regression on patient-specific covariates x i . In a second step, we define a multivariate normal random-effects distribution for b ic . For the random partition of patients into clusters, we assume the PPMx model (Müller and others, 2011) ,
(3.1)
Let n j = |S j | denote the size of the jth cluster. With c(S j ) = M(n j − 1)! and g(x j ) = 1, the random partition (3.1) reduces to the one implied by a DP prior with total mass parameter M. It is also known as a special case of a product partition model (PPM) (Hartigan, 1990) . The PPM allows a general arbitrary cohesion function c(S j ). The PPMx adds to the PPM the similarity function g(x j ) that returns a large value for a set of covariates x j that are judged to be similar and a small value for x j that are judged to be very different.
For example, for a single categorical covariate x i let m j denote the number of distinct levels among x j = (x i ; i ∈ S j ). The similarity function could be g(x j ) = 1/m j . The effect of the additional factor is to increase the prior probability of clusters with experimental units that have similar covariate values. Here "similar" is formalized by g(x j ). In fact, the PPMx model is just another variation of a PPM model with cohesion function c (S j ) = c(S j )g(x j ). For the special case of continuous covariates, an equivalent model with a specific choice of similarity function can be achieved as the posterior distribution in an auxiliary model. Pretend that the (scalar) covariate x i is an observed outcome and add a sampling model p(x | ρ) = j p(x j ). The posterior distribution p(ρ | x) under this auxiliary model has the same form as (3.1). This approach is taken, for example, in Müller and others (1996) and Park and Dunson (2010) . It is practically limited to moderate-sized covariate vectors and preferably a single data type. One can argue that this model amounts to a special choice of similarity function in the PPMx model.
In our implementation, we use the default choices proposed in Müller and others (2011) for the similarity function g * (x j ). Let p denote the number of covariates, i.e. x i = (x i1 , . . . , x i p ), and let x j = {x i , i ∈ S j } denote the th covariate arranged by cluster. We define g(x j ) as a product over all covariates: a, b) . For the binary covariates, we use q(x i | ξ) = Bern(ξ ) and q(ξ ) = Be(0.1, 0.1). The similarity function (3.2) is a computationally convenient way to evaluate the desired homogeneity of clusters with respect to covariates.
We define cluster-specific treatment effects δ j . Subject-specific random effects μ i ∼ N (m, B) and occasion-specific random effects b ic ∼ N (μ i , D) introduce the appropriate dependence across occasions within patients and across repeated measurements within occasions. The model is completed with priors on m, B, D, and other hyperparameters.
Let x = (x 1 , . . . , x n ) denote all covariates and recall that W ict denotes the design vector given by the harmonic functions. In summary, the hierarchical mixed-effects model is
independently across i and c. Here, SPL is the sampling model, CYC is the random-effects distribution for occasion-specific random effects, PAT is a random-effects model for patient-specific random effects, TRT is the prior for sorafenib treatment effects, still conditional on the partition ρ, and PRT is the prior on the random partition. In (3.3), δ j and y i1 are assumed independent, that is, the first occasion (i.e. pretreatment) response does not inform about the treatment effect and thus (2.2) reduces to p(δ n+1 | x n+1 , δ , ρ). Note that μ i could easily be analytically marginalized. We use c = 5, s = 5, d = 10, and S = 100. We use the average (across all patients and occasions) of the occasion-specific maximum likelihood estimate's (m.l.e.'s) to fix a. We use a diagonal matrix with the empirical variance of these m.l.e.'s to fix A. The matrix parameter D 0 is 0.1 · I . Finally, we fix the prior moments (m δ , B δ ) for the treatment effect as (0, 100). The hyperprior parameters (s, S) and (m δ , B δ ) reflect vague prior information. Inference is robust with respect to changes in these parameters. The other choices fix hyperprior parameters in a higher level of the hierarchy. We found little sensitivity of posterior inference with respect to these parameter choices. Inference, however, is sensitive with respect to the choice of the parameters in the similarity function, including V = 1 8
, a = b = 0.1 in q(ξ ) = Be(0.1, 0.1), and B = 4. We view these choices as a part of the prior specification. They reflect the prior judgment on the smoothness of the regression of treatment effects. The interpretation and choice of √ V are similar to the choice of a window-width parameter in a kernel smoothing method.
SIMULATION STUDY
We carried out a simulation study to validate the proposed approach. For the simulation study, we generated responses under (3.3). We simulated data for a hypothetical study with n = 120 patients. For each patient, i = 1, . . . , n, we create sampling times by randomly selecting one of the patients in the study, and copying that patient's sampling times, i.e. the rows in the design matrix X hck , c = 1, . . . , n h for a randomly selected patient h in the actual study. We then fix a simulation truth for μ i as the m.l.e.μ h for the observed patient h. Next we generate the occasion-specific effects b ic . Let V μ denote the empirical variance-covariance matrix of the m.l.e.'sμ h for the observed patients and let D = 0.1V μ . We then generate a simulation truth b ic ∼  N (μ i , D) for the occasion-specific effects. We set up four hypothetical baseline covariates, x i1 , . . . , x i4 , two continuous (x i1 , x i2 ) and two of binary type (x i3 , x i4 ), thereby fixing the simulation truth for the treatment effects δ j . We consider a set of 12 possible patterns of baseline covariates, arising from all possible interactions of one continuous covariate, observed at −1, 0, or 1, and two binary covariates. Each hypothetical patient in the simulation study is assigned baseline covariates by randomly sampling one of these 12 possible patterns for the 3 significant baseline covariates. For the remaining second continuous covariate, we substitute the average covariate value (averaged over the observed patients). We use the K = 12 patterns of the selected three baseline covariates to define clusters and evaluate the "true" treatment effects δ j using a function of the three significant baseline covariates. The simulation truth for the non-linear function is shown in Table 1 (first row). It is
Here I (x i j = a) denotes an indicator for x i j = a. That is, the truth is a linear function of (
The hypothetical response is then generated under model (3.3).
We carry out MCMC posterior simulation to find posterior predictive estimated treatment effects. The entire simulation is repeated M = 100 times to evaluate frequentist summaries under repeated experimentation. The first two rows of Table 1 summarize the results, reporting simulation truth, and mean-squared error under each of 10 out of the 12 combinations of the baseline covariates. The selected 10 combinations are those that are present in the data.
The observed differences in mean squared errors are explained by shrinkage to the overall mean m δ and348
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sampling model:
In contrast to the random partition p(ρ | x), the regression in the sampling model requires a decision for specific effects. For illustration, we include only main effects. Naturally, the main-effects-only regression cannot capture the interactions of the simulation truth. We carried out another simulation, again with model (4.1), but now with additional covariates. We added two additional covariates x i5 ≡ x i1 (1 − x i3 ) and x i6 ≡ x i3 x i4 , to allow a better approximation of the simulation truth. Note that the additional variables still do not match the non-linear nature of f (x i1 ) in the simulation truth. The results are shown in line 4 of the table (marked as "RMSE M3"). Adding the variables did not improve the fit by much. The non-linear nature of f (x i1 ) still prevents a good fit. Only adding one more variable, x i7 ≡ I (x i1 = −1)(1 − x i3 ), would allow the simulation truth to be represented under (4.1). In that case, when the simulation truth happens to be the assumed model in (4.1), we would expect inference under the parsimonious parametric model to be more efficient than under the flexible PPMx model. This is verified in one more simulation, now using the simplified structure in (4.1) as the simulation truth. The third-last row of Table 1 shows the simulation truth, and the last two lines of the table compare the root mean squared error (RMSE) under the two alternative models (3.3) and (4.1) for the same treatment combinations as before. The comparison highlights the price for the increased generality of model (3.3). Performance under the more general model slightly deteriorates compared with inference under the (simpler) simulation truth (4.1).
Finally, we investigated the performance of the proposed approach when the covariates are not carefully chosen. Using the simulation truth given in the first row of Table 1 , we used an analysis model with three irrelevant dummy covariates in addition to the three covariates that appear in the simulation truth. The results are shown in line 5 of the table (marked as "RMSE M4"). In summary, the proposed model (3.3) achieves the desired flexible regression at the expense of a reasonable cost in efficiency when this flexibility is not required.
RESULTS
Posterior inference
We implemented posterior inference under model (3.3) for the earlier introduced study. We ran the MCMC simulation for 10 000 iterations, discarded an initial transient of 1000 iterations and thinned out the Monte Carlo sample by saving every 10th iteration after burn-in. Figure 1 in supplementary material available at Biostatistics online appendix shows fitted profiles.
Fits were equally good across all patients and across diastolic and systolic pressure. The large number of repeat observations for each patient allows precise estimation of the patient and occasion-specific harmonic models. Figure 2 shows the posterior predictive distribution of the effect of sorafenib on blood pressure of a future patient i = n + 1, as a function of patient covariates. Let δ i = δ s i denote the sorafenib effect for the cluster including the ith patient and let y denote the observed data. We report p(δ n+1 | x n+1 , y) as a function of x n+1 . The model only reports effects for combinations of covariates. There is no meaningful marginal main effect of covariates.
The prediction in Figure 2 reflects the variation seen in the data. One can see several patterns. For example, that BPM has a different effect for men (SEX = 1) at the highest BMI group (BMI = 1) than it has for men in the two lower BMI groups. Similarly, one could deduce that BMP has an effect on women with Figure 3 shows some summaries of the posterior random partition model. Figure 3a shows the posterior distribution on the number of clusters K . For comparison, we also estimated a comparable model (4.1) without the additional regression on covariates, moving the regression instead into the mean function. The number of clusters is greatly reduced to around K = 7. The clusters under (3.3) are well identified, up to the trivial label switching problem. Figure 3b shows p i j ≡ p(s i = s j | y) for all pairs of patients. High contrasts with mostly black ( p i j = 1) and white ( p i j = 0) indicate low uncertainty in the posterior distribution on the random partition. The relative importance of different covariates and covariate combination is seen in the summary over clusters. The report of meaningful cluster-specific summaries is complicated by the label-switching problem. That is, the posterior distribution is invariant with respect to arbitrary relabeling of the clusters, making it meaningless to report summaries for a specific cluster. We use an ad hoc method to resolve this problem. Details are reported in Appendix A2 of supplementary material available at Biostatistics online. Figure 4 shows the level of homogeneity of clusters with respect to different covariates. For binary covariates, the plot shows the percentage of patients in each cluster with covariate equal 1. Thus, binary covariates bullets close to 0 or 100 show very homogeneous clusters. For continuous covariates, the plot shows the empirical variance of covariate values within each cluster. Continuous covariates are standardized to zero mean and unit variance across the entire data set. Thus, for continuous covariates, bullets close to 0 indicate very homogeneous clusters. Clusters in a corner indicate a possible interaction when a combination of high or low values of two covariates gives rise to a distinct cluster. The moderate values for the within cluster variance of AGE in most clusters indicate some role of AGE in the model for blood pressure. Similarly, for BMI (note the different scale). Recall that BPM is the indicator for anti-hypertension medication. It is one of the baseline covariates. There is less evidence for an effect of BPM. Most clusters have a mix of BPM = 0 and 1. RACE is very homogeneous in the population to start with. As we see no large clusters that are jointly homogeneous in a pair of covariates, we conclude that there is no suggestion of strong interactions. Moderate interaction of AGE and BMI is suggested by the presence of some clusters in the left lower corner of the first panel (AGE and BMI). Similarly, the plot for BPM and RACE in the right panel includes a cluster of white non-hispanic (RACE = 1) patients who do not take anti-hypertension medication (BPM = 0).
Clusters and regression on covariates
CONCLUSION
We proposed a flexible non-parametric prior for the treatment effects in a mixed-effects model. While non-parametric priors for random-effects distributions in Bayesian inference for mixed-effects models are widely used, the use of similar models for treatment effects is less common. One reason is the need to index the non-parametric model with covariates. We proposed one possible approach. Among the particular strengths of the proposed method is the flexibility to include essentially arbitrary interactions, restricting inference only to interactions of covariates that are observed in the data. An important limitation is the lack of formal inference for such interactions. This is not an issue when the focus is prediction but could be critical in some studies. We considered separate models for SBP and DBP measurements. The large number of repeated measurements for each occasion and patient allows precise and robust estimation of patient-specific parameters. Little would be gained by explicitly modeling the correlation across the two outcomes. If desired, however, generalization to a bivariate outcome would add no additional complications. Finally, we did not discuss details of the posterior MCMC simulation. A detailed description appears in Appendix A1 of supplementary material available at Biostatistics online.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at http://biostatistics.oxfordjournals.org.
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